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ABSTRACT Salmonella enterica serovar Typhimurium strain SL7207 is a genetically
modiﬁed derivative of strain SL1344, which preferentially accumulates in tumors and
can be used as a vehicle for tissue-speciﬁc gene delivery in vivo. Here, we report the
draft genome sequence of SL7207, conﬁrming a purported aroA deletion and four
single-nucleotide polymorphisms compared to SL1344.
Salmonella enterica serovar Typhimurium is most well known for causing acutegastroenteritis. If left untreated, S. Typhimurium infection can lead to systemic
disease resulting in host septic shock and, in extreme cases, death. Despite these
adverse effects, multiple Salmonella serovars have been demonstrated to preferentially
colonize tumor tissue when administered intravenously and delay tumor growth.
SL7207 is one of the most promising strains utilized for this purpose (1). SL7207 is
reported to have a deletion in aroA, resulting in bacterial auxotrophy for two com-
pounds: -aminobenzoic acid and 2,3-dihydroxybenzoate (2). These compounds are
not found in mammalian tissue, rendering the bacteria attenuated in the mammalian
host and lending to its suitability as a therapeutic agent. The parent strain of SL7207,
SL3261, was engineered as a vaccine strain, and it has been used in cancer therapy
studies (1, 3, 4). However, many studies have identiﬁed the tumor-preferential local-
ization of SL7207 when administered intravenously (5–7). Multiple studies have em-
ployed SL7207 for its tumor disruption and tumor-speciﬁc DNA vaccine delivery, as well
as identiﬁed tumor-speciﬁc Salmonella promoters and immune components involved in
Salmonella-tumor localization. Furthermore, bioluminescent SL7207 has been em-
ployed as an agent to identify the location of tumors and metastasis in vivo (8, 9).
However, a detailed analysis of the genetic makeup of this strain is lacking. To gain
a deeper understanding of the mechanisms underlying the antitumor properties of
SL7207, its entire genome was sequenced.
Genomic DNA of S. Typhimurium SL7207 was extracted from a freshly grown single
colony using an Illumina Nextera XT DNA sample kit per the manufacturer’s protocol
(Illumina, USA). Sequencing was performed by Illumina MiSeq using a 2  250
paired-end protocol. Read quality analysis and trimming were conducted using Trim-
momatic and then quality assessed using in-house scripts combined with SAMtools,
BedTools, and BWA-MEM. De novo assembly was conducted with SPAdes version 3.5,
resulting in a total of 68 contigs, with 30 larger than 1,000 bp. The draft genome of
strain SL7207 contains 5,026,283 bp, with 52.16% GC content, and encodes 4,754
coding sequences (CDSs), nine rRNAs, and 84 tRNAs. S. Typhimurium SL1344, in
comparison, encodes 4,605 CDSs, 22 rRNAs, and 85 tRNAs. The contigs of SL7207 were
reordered against the complete genome of SL1344, and aligned using progressive-
Mauve (version 20150226, build 10) (10). A list of single-nucleotide polymorphisms
(SNPs) was generated from Mauve and visually inspected using CLC Genomics Work-
bench version 7.
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The seminal differentiating feature between the ancestral virulent strain, SL1344,
and SL7207 is the 1,194-bp deletion in aroA in SL7207. Furthermore, eight SNPs were
identiﬁed: four intergenic and four intragenic, with two being synonymous and two
being nonsynonymous. SNPs were found in four genes; SNPs in menC (menaquinone
metabolism) (11) and ackA (acetyl-CoA biosynthesis) (12) were synonymous, whereas
SNPs in ptsL (mannose transport) (13, 14) and ycdT (motility) (15) were nonsynonymous.
The genome sequence of SL7207 provides the foundation for further molecular
characterization of the strain in its use as a therapeutic agent in the treatment of cancer.
Accession number(s). This draft genome project has been deposited at DDBJ/
EMBL/GenBank under the accession number MPJV00000000 (BioProject PRJNA350897;
BioSample SAMN05949357). The version described in this paper is the ﬁrst version,
MPJV01000000.
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